BioCentury
ARTICLE | Financial News

Polaris, Arch co-lead series A for MIT spinout Glympse

October 11, 2018 11:22 PM UTC

With $22 million in new series A funding, Glympse Bio Inc. (Cambridge, Mass.) plans to start clinical testing by mid-2019 of its bio-engineered diagnostic for non-alcoholic steatohepatitis (NASH). Glympse is developing injectable bio-engineered activity sensors that emit a signal detectable in urine for diagnostic and drug monitoring purposes.

Polaris Partners and Arch Venture Partners co-led the untranched series A round, announced Oct. 9. Also participating were new investors Charles River Ventures, Gilead Sciences Inc. (NASDAQ:GILD), Yonghua Capital and Inevitable Ventures, along with existing investors GreatPoint Ventures, Heritage Provider Network and Rivas Capital...